April 13, 2018 from 4 p.m. to 5 p.m.
Hess Center for Science & Medicine
1470 Madison Avenue
CSM Building 8-101
Abstract: Checkpoint inhibitors targeting CTLA-4 and
PD-1 enhance the anti-tumor immune response setting
a paradigm for the potential durable clinical benefit
associated with successful immunotherapy. However,
checkpoint inhibitors only demonstrate activity in a
minority of patients with advanced cancer. Studying
non-responsive tumors and the biology of immune
evasion leads to the rational development of novel
therapeutics and combinations, a few examples of
which will be addressed.